LA
OCSAW

Linden Advisors’s Oculis Holding AG Warrants OCSAW Stock Holding History

Linden Advisors’s Portfolio OCSAW Stock Details OCSAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-40,115
Closed -$16.5K – 404
2023
Q1 		$16.5K Buy
+40,115
New +$16.6K ﹤0.01% 400

Other funds holding OCSAW

TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

Linden Advisors's OCSAW Position: Q2 2023 in Review

Linden Advisors sold out of Oculis Holding AG Warrants (OCSAW) in Q2 2023, closing a stake of 40,115 shares — an estimated $16.5K sold.

Linden Advisors first reported a position in OCSAW in Q1 2023 and held it in 1 quarter. The position peaked at $16.5K in Q1 2023. 25 funds tracked by Wall St. Rank hold OCSAW as of Q2 2023.

  • Linden Advisors reported no remaining Oculis Holding AG Warrants position as of Q2 2023 after selling out during the quarter.
  • Linden Advisors sold 40,115 Oculis Holding AG Warrants shares in Q2 2023, an estimated $16.5K.
  • Linden Advisors first reported a position in Oculis Holding AG Warrants in Q1 2023 and held it in 1 quarter.
  • Linden Advisors's Oculis Holding AG Warrants position peaked at $16.5K in Q1 2023.
  • 25 funds tracked by Wall St. Rank held Oculis Holding AG Warrants as of Q2 2023.

Based on Linden Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.